Leu Y L, Roffler S R, Chern J W
Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.
J Med Chem. 1999 Sep 9;42(18):3623-8. doi: 10.1021/jm990124q.
Glucuronide prodrugs of 9-aminocamptothecin were synthesized. Prodrug 4, in which 9-aminocamptothecin was connected to glucuronic acid by an aromatic spacer via a carbamate linkage, was stable in both aqueous solution and human plasma. Prodrug 4 and its potassium salt 12 were 20-80-fold less toxic than 9-aminocamptothecin to human tumor cell lines. The simultaneous addition of beta-glucuronidase and 4 or 12 to tumor cells resulted in a cytotoxic effect equal to that of 9-aminocamptothecin alone. Prodrugs 4 and 12 were over 80 and 4000 times more soluble than 9-aminocamptothecin in aqueous solutions at pH 4.0, respectively. Compounds 4 and 12 may be useful for prodrug monotherapy of tumors that accumulate extracellular lysosomal beta-glucuronidase as well as for antibody-directed enzyme prodrug therapy (ADEPT) of cancer.
合成了9-氨基喜树碱的葡糖醛酸酯前药。前药4中,9-氨基喜树碱通过氨基甲酸酯键经芳香间隔基与葡糖醛酸相连,在水溶液和人血浆中均稳定。前药4及其钾盐12对人肿瘤细胞系的毒性比9-氨基喜树碱低20 - 80倍。向肿瘤细胞中同时加入β-葡糖醛酸酶和4或12会产生与单独使用9-氨基喜树碱相同的细胞毒性作用。前药4和12在pH 4.0的水溶液中的溶解度分别比9-氨基喜树碱高80倍和4000倍以上。化合物4和12可用于对细胞外溶酶体β-葡糖醛酸酶蓄积的肿瘤进行前药单一疗法,以及用于癌症的抗体导向酶前药疗法(ADEPT)。